TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$172.5 Million

Syndax Pharmaceuticals, Inc.

Follow-on Offering

Bookrunner, December 2022

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. (SNDX) (“Syndax” or the “Company”) is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company’s two lead product candidates are SNDX-5613, or revumenib, and SNDX-6352, or axatilimab. Revumenib is being developed for the treatment of MLL-rearranged acute leukemias and nucleophosmin 1 mutant acute myeloid leukemia. Axatilimab is a monoclonal antibody that that targets the colony stimulating factor 1 receptor in chronic graft-versus-host disease as well as idiopathic pulmonary fibrosis.